Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093587 | 0.85 | ALDH1A1 (0.67) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL12223728 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL9502860 | 0.81 | ALDH1A1 (0.62) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL4532875 | 0.80 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL23382244 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL12197486 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL15931713 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL18579724 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL18589075 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNASMN1; SMN2HPGDGLA | |
| SCHEMBL29224422 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNASMN1; SMN2HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103791-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3103791-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3103791-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-3103791-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2170076-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2170076-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| EP-2170076-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002495-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | ALDH1A1 763/4885LMNA 3621/4885SMN1; SMN2 1302/4885 |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | ALDH1A1 763/4885LMNA 3621/4885SMN1; SMN2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.